semaglutide fda indications TrimRX Wegovy® receives FDA approval for

Reward System Modulation: Research suggests that GLP-1 receptor agonists may alter the brain's reward response to food, making it less rewarding to engage in binge eating

patients already covered for OSA are not eligible for Bridge What this means: If you're on Medicare and have been paying out-of-pocket for Zepbound, you may finally get coverage starting July 2026

Combining the two creates a synergistic pulse of GH secretion that mimics natural physiological patterns more closely than either compound alone

This small addition makes a world of difference

A 2021 study published in The New England Journal of Medicine found that patients taking semaglutide lost an average of 15 per cent of their body weight over 68 weeks

It will take more time to determine how effective the pill is in supporting patients' long-term weight loss journeys, whether it helps keep users on GLP-1s for longer than injections do and whether demand for Novo's product will hold in the face of fresh competition from Eli Lilly